The manufacturers of Atomoxetine (Strattera) have updated the Summary of Product Characteristics to include a warning about suicide related behaviour.
Suicide related behaviour is defined as suicidal ideation or a suicide attempt. In double blind clinical trials suicide related behaviour occurred in about 0.5% of patients taking Atomoxetine, this behaviour was absent in the placebo arms of the studies.
Action: Patients (and their parents or guardians) should be made aware of this new information. Any behavioural changes including depression, suicidal ideation or suicide attempts should prompt a rapid referral for re-assessment and a change of treatment if necessary.
|« New MeReC Extra||Flomax Update »|